RxDoctor Payments Data

Steven Ogden, MD

Family Medicine · Bogalusa, LANPI 1093080384

Payments from drug & device makers

$6,219in general payments, 2019–2025

Across 378 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$515
  • AstraZeneca$501
  • Boehringer Ingelheim$440
  • Lilly USA, LLC$423
  • Novo Nordisk$422
  • Pfizer$408
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$6,12298%
  • Education$962%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,219 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$77,095
Medicare patients
257
Services billed
1,013

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide283$315,031
JardianceEmpagliflozin124$151,841
EliquisApixaban158$97,630
JanuviaSitagliptin Phosphate79$91,557
FarxigaDapagliflozin Propanediol93$91,437
MounjaroTirzepatide74$77,229
Trelegy ElliptaFluticasone/Umeclidin/Vilanter90$64,739
TrulicityDulaglutide34$48,218
LinzessLinaclotide119$46,312
Soliqua 100-33Insulin Glargine/Lixisenatide51$45,792
EntrestoSacubitril/Valsartan55$43,831
XareltoRivaroxaban20$22,679
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$20,629
RybelsusSemaglutide11$16,211
Combivent RespimatIpratropium/Albuterol Sulfate33$15,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$422$331,242294 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat$440$188,373201 claims
Lilly USA, LLCMounjaro, Trulicity$423$125,447108 claims
PfizerEliquis, Premarin$408$100,404170 claims
AstraZenecaFarxiga, Symbicort$501$96,863112 claims
MerckJanuvia$185$91,55779 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy$342$88,858151 claims
AbbVieLinzess, Vraylar, Creon$515$68,081142 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$128$45,79251 claims
NovartisEntresto$98$43,83155 claims
Johnson & JohnsonXarelto$163$22,67920 claims
BayerKerendia$394$11,89519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Bogalusa

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →